BACKGROUND: In multiple myeloma, progression within 24 months (POD24) is a strong adverse prognostic factor. However, its impact on overall survival (OS) remains underexplored through machine learning.
T-cell receptor (TCR) repertoire diversity has been implicated in the progression and prognosis of multiple myeloma (MM). This study aimed to evaluate the association between T-cell clonality, immune response, and clinical outcomes in patients with p...
Clinica chimica acta; international journal of clinical chemistry
Jul 15, 2025
OBJECTIVE: Immunoglobulin D (IgD) myeloma is a rare subtype of multiple myeloma (MM), comprising approximately 1 %-2 % of all MM cases. Owing to the diminished levels of IgD in serum, IgD MM manifests as subtle M protein spikes in routine serum elect...
PANoptosis is closely associated with tumorigenesis and therapeutic response, yet its role in multiple myeloma (MM) remains unclear. This study analyzed bulk transcriptomic and clinical data from the TCGA and GEO databases to identify seven PANoptosi...
Accurate medical image segmentation is crucial for enabling automated clinical decision procedures. However, existing supervised deep learning methods for medical image segmentation face significant challenges due to their reliance on extensive label...
BACKGROUND: Individualized treatment decisions for multiple myeloma (MM) patients require accurate risk stratification that accounts for patient-specific consequences of cytogenetic abnormalities on disease progression.
Delayed diagnosis of systemic light chain (AL) amyloidosis is common and associated with worse survival and early mortality. Current diagnosis still relies on invasive tissue biopsies, highlighting the need for sensitive, noninvasive biomarkers for e...
Journal of applied clinical medical physics
Mar 11, 2025
BACKGROUND: Multiple myeloma (MM) induces temporal alterations in bone structure, such as osteolytic bone lesions, which are challenging to identify through manual image interpretation. The large variation in radiologists' assessments, even at expert...
Multiple myeloma (MM) is a prevalent hematologic malignancy characterized by abnormal proliferation of cloned plasma cells. Given the aggressive nature and drug resistance of MM cells, identification of novel genes could provide valuable insights for...
Multiple myeloma is a hematologic malignancy characterized by the proliferation of abnormal plasma cells in the bone marrow. Despite therapeutic advancements, there remains a critical need for reliable, noninvasive methods to monitor multiple myeloma...
Join thousands of healthcare professionals staying informed about the latest AI breakthroughs in medicine. Get curated insights delivered to your inbox.